// App-Quantinova.ai

4877 : Discovery of novel and potent inhibitors of indoleamine-2,3-dioxygenase (IDO1) for cancer immunotherapy

Researchers

Presenter

  • Shengyang Liu

Principal Investigators

  • Yue Liang

  • Hongli Guo

  • Xiaogang Ye

  • Zhiheng Wu

  • Fang Bao

  • Heping Yang

  • Yaxian Cai

  • Gangjing Yang

  • Longsheng Wang

  • Fang Liu

  • Guangliang Fu

  • Xiaolei Liu

  • Jiangang Du

  • Ping Qin

  • Yuanfei Ma

  • Panhu Zhu

  • Yajun Yu

  • Chen Ma

  • Pei Wang

  • Liping Zhao

  • Yuxun Wang

  • Daxin Gao

  • Qun Li

Medical Centers

  • Shanghai Denovo Pharmatech, Zhangjiang New Area, Shanghai, China.

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

  • Indoleamine 2,3-dioxygenase 1

Drug/Treatment

  • tryptophan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved